Wim E Hennink
Overview
Explore the profile of Wim E Hennink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
428
Citations
9245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dasgupta A, May J, Klinkenberg G, Besse H, Buhl E, Moeckel D, et al.
J Control Release
. 2025 Feb;
380:818-828.
PMID: 39956394
Brain tumors are difficult to target and treat. The blood-brain barrier (BBB) limits drug delivery to pathological sites, and standard mono-chemotherapy typically results in suboptimal efficacy and development of drug...
2.
van Straten D, Bimbo J, Hennink W, Vermonden T, Schiffelers R
Pharmaceutics
. 2025 Jan;
17(1).
PMID: 39861774
Background/objectives: Glioblastoma is the most common and lethal primary brain tumor. Patients often suffer from tumor- and treatment induced vasogenic edema, with devastating neurological consequences. Intracranial edema is effectively treated...
3.
Timmers M, Kong M, Schuckman P, Meulemans T, Rijcken C, Hennink W, et al.
Chemistry
. 2024 Dec;
31(15):e202403589.
PMID: 39660486
Active Pharmaceutical Ingredients (APIs) may benefit from a carrier to improve their pharmacokinetic and pharmacodynamic properties. Core-crosslinked polymeric micelles (CCPMs) are carriers for hydrophobic small molecule APIs. In CCPMs, APIs...
4.
Mihyar R, Shalmani A, Wildt V, Sheybanifard M, Wang A, May J, et al.
J Control Release
. 2024 Sep;
375:614-626.
PMID: 39316925
Controlled manufacturing and long-term stability are key challenges in the development and translation of nanomedicines. This is exemplified by the mRNA-nanoparticle vaccines against COVID-19, which require (ultra-)cold temperatures for storage...
5.
Hebels E, Dietl S, Timmers M, Hak J, van den Dikkenberg A, Rijcken C, et al.
Bioconjug Chem
. 2023 Dec;
34(12):2375-2386.
PMID: 38079189
Nanocarriers have shown their ability to extend the circulation time of drugs, enhance tumor uptake, and tune drug release. Therapeutic peptides are a class of drug compounds in which nanocarrier-mediated...
6.
Shalmani A, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl E, et al.
Drug Deliv Transl Res
. 2023 Nov;
14(10):2642-2654.
PMID: 37962836
Nanomedicine holds promise for potentiating drug combination therapies. Increasing (pre)clinical evidence is available exemplifying the value of co-formulating and co-delivering different drugs in modular nanocarriers. Taxanes like paclitaxel (PTX) are...
7.
Casadidio C, Hartman J, Mesquita B, Haegebaert R, Remaut K, Neumann M, et al.
Mol Pharm
. 2023 Oct;
20(11):5515-5531.
PMID: 37811785
Ovarian cancer is one of the most lethal gynecological cancers in the world. In recent years, nucleic acid (NA)-based formulations have been shown to be promising treatments for ovarian cancer,...
8.
Sheikhi M, Sharifzadeh M, Hennink W, Firoozpour L, Hajimahmoodi M, Khoshayand M, et al.
Eur J Pharm Biopharm
. 2023 Oct;
192:56-61.
PMID: 37783361
Due to the lack of pharmacopeia guidelines for injectable microspheres based on poly (D, L-lactide-co-glycolide) (PLGA), an internal method validation is a critical prerequisite for quality assurance. One of the...
9.
Hebels E, van Steenbergen M, Haegebaert R, Seinen C, Mesquita B, van den Dikkenberg A, et al.
Langmuir
. 2023 Aug;
39(34):12132-12143.
PMID: 37581242
Core-crosslinked polymeric micelles (CCPMs) are an attractive class of nanocarriers for drug delivery. Two crosslinking approaches to form CCPMs exist: either via a low-molecular-weight crosslinking agent to connect homogeneous polymer...
10.
Douka S, Brandenburg L, Casadidio C, Walther J, Garcia B, Spanholtz J, et al.
J Control Release
. 2023 Aug;
361:455-469.
PMID: 37567506
Natural killer (NK) cells participate in the immune system by eliminating cancer and virally infected cells through germline-encoded surface receptors. Their independence from prior activation as well as their significantly...